Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.78
+2.431.13%
Post-market: 216.780.00000.00%19:30 EDT
Volume:722.35K
Turnover:156.95M
Market Cap:32.00B
PE:38.50
High:219.12
Open:217.76
Low:215.00
Close:214.35
52wk High:222.15
52wk Low:131.52
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.01
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.66

Loading ...

Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Simply Wall St.
·
Jun 29

Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs

Simply Wall St.
·
Jun 27

Biogen Inc. Stock Advances 7.0%, Outperforms Peers

Dow Jones
·
Jun 27

Movement Alert|Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline

Market Focus
·
Jun 26

Early notable gainers among liquid option names on June 26th

TIPRANKS
·
Jun 26

Biogen Scales Back Apellis Programs, Trims Research Roles After $5.6 Billion Buyout

Reuters
·
Jun 26

Biogen Spokesperson: Biogen Made the Decision to Pause or Terminate Investment in the Majority of Legacy Apellis Research Programs

THOMSON REUTERS
·
Jun 26

Biogen Spokesperson - Conducting Comprehensive Review of Former Apellis Clinical & Preclinical Portfolio to Further Evaluate Strategic Fit

THOMSON REUTERS
·
Jun 26

Biogen Spokesperson: a Small Number of Roles Within the Research Organization Have Been Eliminated

THOMSON REUTERS
·
Jun 26

Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation

Simply Wall St.
·
Jun 25

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 25

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 23

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA)

TIPRANKS
·
Jun 22

Biogen Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 19

Sector Update: Healthcare Stocks Decline Thursday Afternoon

MT Newswires Live
·
Jun 19

Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says

MT Newswires Live
·
Jun 18

Biogen Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Jun 18

Biogen Rated Buy as RayThera Acquisition Bolsters Immunology Pipeline and Long-Term Growth Prospects

TIPRANKS
·
Jun 18

Biogen Inc : Morgan Stanley Raises Target Price to $224.00 From $206.00

THOMSON REUTERS
·
Jun 18

Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating

MT Newswires Live
·
Jun 18